Haematologica
HAEMATOL/2018/211490
Version 3

A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models

Aïda Falgàs, Victor Pallarès, Ugutz Unzueta, María Virtudes Céspedes, Irene Arroyo-Solera, María José Moreno, Alberto Gallardo, María Antonia Mangues, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Ramon Mangues, and Isolda Casanova

Disclosures: This work was supported by Instituto de Salud Carlos III (ISCIII, Co-funding from FEDER) [PI18/00650, PIE15/00028, PI15/00378 and EU COST Action CA 17140 to R.M., FIS PI17/01246, RD12/0036/0071 and FIS PI14/00450 to J.S.; CP15/00163 to M.V.C.; FIS PI15/00272 to E.V.]; Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (FEDER) (grant BIO2016-76063-R, AEI/FEDER, UE) to A.V.; CIBER-BBN [CB06/01/1031 and 4NanoMets to R.M., and VENOM4CANCER to A.V.]; AGAUR [2017 FI_B 00680 to A.F.; 2017-SGR-865 to R.M., 2017-SGR-1395 to J.S. and 2017SGR-229 to A.V.]; Josep Carreras Leukemia Research Institute [P/AG to R.M.]; a grant from the Cellex Foundation, Barcelona [to J.S.]; a grant from La Generalitat de Catalunya (PERIS) [SLT002/16/00433 to J.S.]; a grant from Fundacion MMA [AP166942017 to M.V.C.] and the Generalitat de Catalunya CERCA Programme. The work was also funded by Grants PERIS SLT006/17/00093 [to U.U.], Fundación Española de Hematología y Hemoterapia (FEHH) [to V.P.] and a Miguel Servet contract from ISCIII to M.V.C. The bioluminescent follow-up of cancer cells and nanoparticle biodistribution and toxicity studies has been performed in the ICTS-141007 Nanbiosis Platform, using its CIBER-BBN Nanotoxicology Unit (http://www.nanbiosis.es/portfolio/u18-nanotoxicology-unit/). Protein production has been partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER-BBN/ IBB (http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/). UU, EV, AV, MVC, RM and IC are cited as inventors in a patent application (EP11382005.4) covering the therapeutic use of T22. All other authors report no conflicts of interest in this work.

Contributions: Conception and design: AF, VP, AV, EV, RM and IC; development of methodology: AF, VP, UU, IAS, MVC, MAM and IC; acquisition of data: AF, VP, MJM and UU; histopathological analysis: AF, VP and AG; analysis and interpretation of data: AF, VP, JS, AV, EV, RM and IC; writing, review, and/or revision of manuscript: AF, VP, RM, IC, AV, UU and EV. Study supervision: RM, IC, AV and EV. All authors critically revised and approved the final manuscript.